Dmitry Samarsky

Company: Sirnaomics

Job title: Chief Technology Officer


Examining the Flexibility of RNAi-Based Therapy: Targeting C3, C5 & Complement Factor B 2:40 pm

Sirnaomics’ approach of using oligonucleotides in hepatocytes for gene/protein targeting Identify the benefits of a combination approach with STP247G’s ability to target complement Factor CFB/C5 simultaneously Explore the scientific decisions behind which factor to target for certain diseasesRead more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.